P Colombat1, N Brousse2, G Salles3, F Morschhauser4, P Brice5, P Soubeyran6, V Delwail7, E Deconinck8, C Haioun9, C Foussard10, C Sebban11, H Tilly12, C Thieblemont5, L Bergougnoux13, F Lazreg13, P Solal-Celigny14. 1. Department of Hematology and Cellular Therapy, Bretonneau University hospital, Tours. Electronic address: colombat@med.univ-tours.fr. 2. Department of Pathology, Necker University hospital, Paris. 3. Department of Hematology/Oncology, Lyon Sud University hospital, Pierre-Bénit. 4. Department of Hematology, Claude Huriez University hospital, Lille. 5. Department of Hematology, Saint-Louis University hospital, Paris. 6. Department of Medicine, Bergonie Institute, Bordeaux. 7. Department of Hematology, Poitiers University hospital, Poitiers. 8. Department of Hematology, Jean Minjoz University hospital, Besançon. 9. Department of Hematology, Henri Mondor University hospital, Creteil. 10. Department of Hematology, Hôtel Dieu University hospital, Angers. 11. Department of Medical Oncology, Léon Bérard Center, Lyon. 12. Department of Oncology, Henri Becquerel Center, Rouen. 13. Department of Hematology, Roche, Neuilly-sur-Seine. 14. Oncoradiotherapy and Hematology center, Jean Bernard Center, Le Mans, France.
Abstract
BACKGROUND: The purpose of this study was to report long-term results of rituximab induction monotherapy in patients with low-tumor-burden follicular lymphoma (LTBFL). PATIENTS AND METHODS: Of 49 first-line LTBFL patients who received weekly doses of rituximab (375 mg/m(2)), 46 have been followed with a long-term analysis of clinical and molecular responses. RESULTS: Best clinical response (at any staging within a year following treatment) was 80%, 24 (52%) patients had complete or unconfirmed complete response, 13 (28%) had partial response and 9 (20%) had stable or progressive disease. Of 31 patients having a positive bcl2-JH rearrangement, 15 (48%) became negative following treatment. After 83.9 months of follow-up (95% confidence interval 6.4-92.8 months), the median progression-free survival is 23.5 months and overall survival (OS) is 91.7%. Five patients died (one progression, one myelodysplasia, one diffuse large B-cell lymphoma and two solid tumors). Seven patients (15%) are progression-free including five who are bcl2 informative. No unexpected long-term adverse event has been observed. CONCLUSION: A significant proportion of patients remain progression-free 7 years after a single 4-dose rituximab treatment in first-line LTBFL. The 7-year overall survivalOS is very high in this selected population of patients.
BACKGROUND: The purpose of this study was to report long-term results of rituximab induction monotherapy in patients with low-tumor-burden follicular lymphoma (LTBFL). PATIENTS AND METHODS: Of 49 first-line LTBFL patients who received weekly doses of rituximab (375 mg/m(2)), 46 have been followed with a long-term analysis of clinical and molecular responses. RESULTS: Best clinical response (at any staging within a year following treatment) was 80%, 24 (52%) patients had complete or unconfirmed complete response, 13 (28%) had partial response and 9 (20%) had stable or progressive disease. Of 31 patients having a positive bcl2-JH rearrangement, 15 (48%) became negative following treatment. After 83.9 months of follow-up (95% confidence interval 6.4-92.8 months), the median progression-free survival is 23.5 months and overall survival (OS) is 91.7%. Five patients died (one progression, one myelodysplasia, one diffuse large B-cell lymphoma and two solid tumors). Seven patients (15%) are progression-free including five who are bcl2 informative. No unexpected long-term adverse event has been observed. CONCLUSION: A significant proportion of patients remain progression-free 7 years after a single 4-dose rituximab treatment in first-line LTBFL. The 7-year overall survivalOS is very high in this selected population of patients.
Authors: Brad S Kahl; Fangxin Hong; Michael E Williams; Randy D Gascoyne; Lynne I Wagner; John C Krauss; Thomas M Habermann; Lode J Swinnen; Stephen J Schuster; Christopher G Peterson; Mark D Sborov; S Eric Martin; Matthias Weiss; W Christopher Ehmann; Sandra J Horning Journal: J Clin Oncol Date: 2014-08-25 Impact factor: 44.544
Authors: Franz Buchegger; Steven M Larson; Jean-Pierre Mach; Yves Chalandon; Pierre-Yves Dietrich; Anne Cairoli; John O Prior; Pedro Romero; Daniel E Speiser Journal: Clin Dev Immunol Date: 2013-11-26